Replies to post #74098 on Biotech Values

[DewDiligence]

MRK is off 8%, but this is probably not because investors think MRK is overpaying for SGP. Rather, the reason for the drop is probably that the merger has an Achilles heel with respect to SGP’s ex-US rights to the blockbuster, Remicade.